001     306517
005     20251212125553.0
024 7 _ |a 10.1021/acs.jpcb.5c05015
|2 doi
024 7 _ |a pmid:41273337
|2 pmid
024 7 _ |a 1520-6106
|2 ISSN
024 7 _ |a 1520-5207
|2 ISSN
037 _ _ |a DKFZ-2025-02582
041 _ _ |a English
082 _ _ |a 530
100 1 _ |a Adelabu, Isaiah
|0 0000-0002-9475-0851
|b 0
245 _ _ |a Multidimensional pH-Temperature Mapping of SABRE-SHEATH 13C Hyperpolarization of [1-13C]Pyruvate.
260 _ _ |a Washington, DC
|c 2025
|b Americal Chemical Society
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1765540520_396855
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a J. Phys. Chem. B 2025, 129, 12401−12409
520 _ _ |a Hyperpolarized [1-13C]pyruvate has emerged as a next-generation molecular probe for in vivo metabolic flux imaging in deep tissue. This molecular contrast agent is now under evaluation in over 50 clinical trials, according to clinicaltrials.gov. Hyperpolarized [1-13C]pyruvate is produced through dissolution dynamic nuclear polarization (d-DNP) for clinical research use. This remarkable hyperpolarization technique is regarded as expensive (>2 M equipment cost) and slow (1 h production). One alternative hyperpolarization technique called Signal Amplification By Reversible Exchange (SABRE) in SHield Enables Alignment Transfer to Heteronuclei (SABRE-SHEATH) has recently garnered substantial attention for production of hyperpolarized [1-13C]pyruvate quickly (in 1 min) and inexpensively (<$20K equipment). It has been successfully demonstrated in vivo for metabolic imaging of cancer. This technique relies on the simultaneous chemical exchange of parahydrogen, acting as a source of nuclear spin order, and [1-13C]pyruvate on a Ir-IMes polarization transfer catalyst at ∼0.4 μm magnetic field. The SABRE catalyst forms two kinds of complexes with parahydrogen-derived hydrides, pyruvate, and dimethyl sulfoxide, acting as a critically important coligand; however, only the complex that binds pyruvate in an equatorial position can release hyperpolarized [1-13C]pyruvate into the solution to enable bulk HP [1-13C]pyruvate production for use in molecular imaging and other applications. Here, we investigate the interplay of pH and temperature with the SABRE-SHEATH hyperpolarization of [1-13C]pyruvate. Temperature and pH modulate this process in remarkable and complementary ways, greatly affecting pyruvate exchange and 13C relaxation dynamics. The overall process is optimal at pH (methanol) of 6.5-7.7 and a temperature of 6 °C: indeed, the catalyst-bound pyruvate exhibits high 13C polarization levels in excess of 25%. The 13C polarization results are additionally supported by 13C relaxation dynamics at a polarization field of 0.4 microtesla. These results provide deeper understanding of the SABRE-SHEATH process and pave the way to further improve the efficiency of the hyperpolarization technique.
536 _ _ |a 899 - ohne Topic (POF4-899)
|0 G:(DE-HGF)POF4-899
|c POF4-899
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
700 1 _ |a Gyesi, Joseph
|b 1
700 1 _ |a Chowdhury, Md Raduanul H
|b 2
700 1 _ |a Oladun, Clementinah
|b 3
700 1 _ |a Nantogma, Shiraz
|b 4
700 1 _ |a Foren, Grant
|b 5
700 1 _ |a Samoilenko, Anna
|b 6
700 1 _ |a Ettedgui, Jessica
|0 0000-0003-4903-1724
|b 7
700 1 _ |a Swenson, Rolf E
|b 8
700 1 _ |a Krishna, Murali C
|b 9
700 1 _ |a TomHon, Patrick
|0 0000-0003-3202-9812
|b 10
700 1 _ |a Theis, Thomas
|0 0000-0001-6779-9978
|b 11
700 1 _ |a de Maissin, Henri
|b 12
700 1 _ |a Schmidt, Andreas
|0 P:(DE-He78)17e270765cb79a4a3b19014bbb1095bb
|b 13
|u dkfz
700 1 _ |a Goodson, Boyd M
|0 0000-0001-6079-5077
|b 14
700 1 _ |a Scofield, Sydney
|b 15
700 1 _ |a Stilgenbauer, Lukas
|b 16
700 1 _ |a Sadagurski, Marianna
|b 17
700 1 _ |a Chekmenev, Eduard Y
|0 0000-0002-8745-8801
|b 18
773 _ _ |a 10.1021/acs.jpcb.5c05015
|g p. acs.jpcb.5c05015
|0 PERI:(DE-600)2006039-7
|p 12401−12409
|t The journal of physical chemistry / B
|v 129
|y 2025
|x 1520-6106
909 C O |p VDB
|o oai:inrepo02.dkfz.de:306517
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 13
|6 P:(DE-He78)17e270765cb79a4a3b19014bbb1095bb
913 1 _ |a DE-HGF
|b Programmungebundene Forschung
|l ohne Programm
|1 G:(DE-HGF)POF4-890
|0 G:(DE-HGF)POF4-899
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-800
|4 G:(DE-HGF)POF
|v ohne Topic
|x 0
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1150
|2 StatID
|b Current Contents - Physical, Chemical and Earth Sciences
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-20
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-20
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J PHYS CHEM B : 2022
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-20
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-20
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2024-12-20
920 1 _ |0 I:(DE-He78)FR01-20160331
|k FR01
|l DKTK Koordinierungsstelle Freiburg
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)FR01-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21